Vor Biopharma Inc.
$13.44
-0.037%Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -0.2).
Valuation inputs: P/E -0.2, earnings yield N/A, momentum -0.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE +4.2%, ROIC -84.6%).
Profitability stack: net margin 0.0%, ROE +4.2%, ROIC -84.6%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +135.4%, momentum -0.0%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Vor Biopharma Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Vor Biopharma Inc. Fair Value Envelope
No Revenue Data
VOR has not reported any revenue values in the available annual periods.
Vor Biopharma Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
VOR has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
VOR has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
VOR has not reported any net profit margin values in the available annual periods.
Vor Biopharma Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Vor Biopharma Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Vor Biopharma Inc. Street Expectations Map
Wall Street analysts project that VOR stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 31.67, with estimates ranging from a low of 18.00 to a high of 46.00.
The consensus 1-year price target stands at 31.67, with estimates ranging from a low of 18.00 to a high of 46.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Vor Biopharma Inc. Insider Positioning
During the last 12 months, insiders have purchased $74.39M and sold $62.56M worth of VOR shares, resulting in $11.83M of net buying activity.
3 Months
0
0.00
2.1M
35.14M
-35.1M
-$35.14M
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
10.1M
257.60K
3.2M
20.39M
-20.1M
-$20.13M
9-12 Months
83.3M
74.13M
3.5M
7.03M
+67.1M
+$67.11M
Top Buyers
Kress Jean-Paul
Director, Officer: Ceo And Chairman
$74.13M
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$139K
Reed Sarah Burgess
Director
$119K
Top Sellers
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$44.55M
Reprogrammed Interchange Llc
10 Percent Owner
$18.01M
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $11.83M net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider buyers vs. 2 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
No Dividend Yield Data
VOR has not reported any dividend yield values in the available annual periods.
vor Dividend History
Learning Layer
Related Guides
Build conviction on VOR by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.